Apriligen

Apriligen is a biotechnology company focused on advancing non-viral gene editing technologies to create next-generation cell and gene therapies. The company's proprietary platform enables the precise, site-specific integration of large DNA sequences into the human genome without the need for viral vectors, addressing key limitations in safety and manufacturing. Founded by experts from the University of Minnesota, Apriligen is applying its technology to develop a pipeline of CAR-T cell therapies for oncology and treatments for genetic diseases. Their approach aims to streamline the production of engineered cells while enhancing therapeutic efficacy and reducing costs. By utilizing a non-viral delivery system, the company seeks to overcome the cargo capacity and immunogenicity issues often associated with traditional viral-based methods.